[Comparison of the results of the treatment with pirenzepine combined with cimetidine and sucralfate of stomach ulcer resistant to cimetidine].
Increased inhibition of gastric acid release through simultaneous blockade of H2-receptors and muscarine-receptors or administration of gastroprotective agent is theoretically justified in patients with peptic ulcer unresponsive to cimetidine. The study involved 70 patients with peptic ulcer previously treated with cimetidine in daily dose 1000 mg for 6 weeks without an effect. Patients were divided into two groups: group 1 treated with cimetidine plus pirenzepine, and group 2 given sucralfate in daily dose 4.0 g. Pirenzepine to patients of group 1 was given in a single dose of 50 mg before bedtime. Both groups were comparable in age, sex, disease onset, smoking, gastric acid secretion, and ulcer size. Healing was evaluated with endoscopic technique following 2 and weeks of therapy. Ulceration healed up within 2 weeks in 40% of patients treated with cimetidine combined with pirenzepine and in 31.4% patients treated with sucralfate. After 4 weeks, healing of ulceration was 71.4% and 68.6%, respectively. Large ulcers (over 1 cm in diameter) and previous partial gastrectomy did not affect healing rate. The obtained results suggest that administered therapies enable recovery in over 2/3 of patients with peptic ulcer unresponsive to a 6-week therapy with cimetidine alone.
Kozuszyńska
M
M
Oddziału Gastroenterologii Wojewódzkiego Szpitala Zespolonego im. Jedrzeja Sniadeckiego w Białymstoku.
Stasiewicz
J
J
Janke
A
A
Szałaj
W
W
Namiot
Z
Z
D002927:Cimetidine / Q000008:administration & dosage*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D010890:Pirenzepine / Q000008:administration & dosage*; D013276:Stomach Ulcer / Q000188:drug therapy*; D013392:Sucralfate / Q000008:administration & dosage*; D014945:Wound Healing / Q000187:drug effects
D010890:Pirenzepine; D013392:Sucralfate; D002927:Cimetidine
Porównanie wyników leczenia pirenzepina łacznie z cymetydyna oraz sukralfatem chorych z wrzodem zoładka opornym na stosowanie samej cymetydyny.